A recent study suggests that patients who come off blockbuster slimming jabs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who stop traditional diet and exercise programs.
Published data in a leading health publication points out that while obese people can lose substantial amounts of their body weight while on the medication, the weight comes back at an estimated rate of 0.8 kg per month after stopping.
"Individuals buying such medications must be cognizant of the risk of fast weight regain when the medication is stopped," cautioned lead investigator Dr. Susan Jebb.
This pace of regain implies a return to original mass within about one and a half years.
Comparing Approaches
The study, which looked at dozens of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with conventional dieting.
The team point out that people who lose weight through diet and exercise typically have a slower creep back—around 100 grams monthly—once they finish.
The Reason for the Fast Rebound
Nutrition scientists propose the way of the drugs accounts for the amplified rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than the body's typical production might result in the system to generate a reduced amount of its endogenous hormone, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement leads to appetite is uncontrolled, making overeating much more probable."
A Chronic Condition?
Health authorities suggest the jabs for individuals with weight-linked medical conditions, accompanied by recommended lifestyle changes.
Many experts contend that, due to the significant potential of relapse, the therapy should be considered long-term.
This perspective is supported by drug manufacturers, who note that the results "highlight the chronic nature of excess weight," comparing it to managing diseases like hypertension.
User Accounts
Users who have stopped the medication explain a intense resurgence of cravings.
"I experienced a trigger flipping and you're instantly starving," recalled a patient.
This difficulty is exacerbated if individuals have not developed sustainable lifestyle or habit modifications during treatment.
Growing Adoption
Recent estimates show that a significant number of people in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Adoption is more common among females compared to males.
- The 40s and 50s age group shows the highest usage rates.
- Many access the medications through private prescriptions rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a standalone cure and maintained weight loss hinges on ongoing behavioural changes.
